Gabrielle Placide
Internal Medicine · Washington, DCNPI 1245450345
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 249 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Viiv Healthcare Company at 33.3% of the total. Reporting peaked in 2024 at $3,414 and has fallen 58.7% since, to $1,412 in 2025. Among internal medicine clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 249 payments — averaging $45.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$4K
- Gilead$3K
- Neurocrine Biosciences, Inc.$1K
- AbbVie$929
- Janssen Products, LP$540
- Johnson & Johnson$429
- plus $1K from 9 others
What the payments were for
- Food & beverage$11,12699%
- Education$1591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 87 | $3,757 |
| Gilead | 75 | $3,129 |
| Neurocrine Biosciences, Inc. | 11 | $1,103 |
| AbbVie | 18 | $929 |
| Janssen Products, LP | 6 | $540 |
| Johnson & Johnson(2 entities) | 19 | $429 |
| Otsuka America Pharmaceutical, Inc. | 8 | $407 |
| Teva Pharmaceuticals USA, Inc. | 9 | $263 |
| Lundbeck LLC | 7 | $189 |
| Merck | 3 | $160 |
| GSK | 1 | $124 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| E.r. Squibb & Sons, L.L.C. | 2 | $85 |
| Exact Sciences | 1 | $25 |
| Alkermes, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,285 in reported general payments places this provider in the 95th percentile of 645 internal medicine providers in District of Columbia.
See all internal medicine providers in District of Columbia →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 110 | $434,406 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 32 | $145,326 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 33 | $124,604 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 27 | $90,518 |
| DescovyEmtricitabine/Tenofov Alafenam | 27 | $59,806 |
| DovatoDolutegravir Sodium/Lamivudine | 15 | $39,915 |
| TrulicityDulaglutide | 13 | $11,928 |
| JardianceEmpagliflozin | 19 | $11,075 |
| Spiriva HandihalerTiotropium Bromide | 17 | $8,699 |
| EliquisApixaban | 12 | $6,700 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $6,602 |
| MyrbetriqMirabegron | 12 | $4,988 |
| Atovaquone | 15 | $4,361 |
| SymbicortBudesonide/Formoterol Fumarate | 13 | $2,936 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 116 | $2,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $3,129 | $618,815170 claims |
| Janssen Products, LPSymtuza | $540 | $145,32632 claims |
| Viiv Healthcare CompanyDovato | $3,757 | $39,91515 claims |
| GSKAnoro Ellipta | $124 | $6,60215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 645 internal medicine providers in District of Columbia.
Other internal medicine in Washington
- Andrea SingerWashington$850K
- Kathryn SowerwineWashington$831K
- Douglas WardWashington$233K
- Geoffrey GibneyWashington$185K
- Kevin GriffithsWashington$180K
- Bruce RashbaumWashington$86K
- Jessica Wang-MemoliWashington$56K
- Dana McGintyWashington$47K
- Geeta NayyarWashington$46K
- Marie BorumWashington$42K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.